Rationale: Numerous studies have proposed that glycogen synthase kinase (GSK)-3␤ is a central regulator of the hypertrophic response of cardiomyocytes. However, all of this work has relied on overexpression of GSK-3␤, expression of constitutively active mutants, or small molecule inhibitors with documented off-target effects. Genetic loss of function approaches have not been used in the adult mouse because germ-line deletion of GSK-3␤ is embryonic-lethal. Objective: This study was designed to define the role played by GSK-3␤ in pressure overload (PO)-induced hypertrophy and remodeling following myocardial infarction (MI). Methods and Results: We used a mouse model that allows inducible, cardiomyocyte-specific deletion of GSK-3␤ in the adult knockout. Surprisingly, we find that knockout mice exposed to PO induced by thoracic aortic constriction exhibit a normal hypertrophic response. Thus, in contrast to virtually all prior published studies, GSK-3␤ appears to play at most a minor role in the hypertrophic response to PO stress. However, GSK-3␤ does regulate post-MI remodeling because the GSK-3␤ knockouts had less left ventricular dilatation and betterpreserved left ventricular function at up to 8 weeks post-MI despite demonstrating significantly more hypertrophy in the remote myocardium. Deletion of GSK-3␤ also led to increased cardiomyocyte proliferation following PO and MI. Conclusions: Deletion of GSK-3␤ protects against post-MI remodeling and promotes stress-induced cardiomyocyte proliferation in the adult heart. These studies suggest that inhibition of GSK-3␤ could be a strategy to both prevent remodeling and to promote cardiac regeneration in pathological states. (Circ Res. 2010;106:1635-1645.)
C ardiomyocytes are terminally differentiated cells that respond to different stresses such as pressure stress (eg, hypertension or aortic valvular disease) and cardiac injury leading to myocyte loss (eg, myocardial infarction) by undergoing hypertrophy. As cardiomyocytes hypertrophy, they go through specific characteristic changes regardless of pathological stimulus. These alterations typically include conversion to a fetal gene expression profile, increased protein synthesis, and changes in metabolism. 1, 2 Over time, hypertrophy can progress to heart failure. Heart failure is characterized by progressive cell loss, extracellular matrix remodeling and contractile dysfunction. It is unclear how (or if) hypertrophy contributes to these phenotypic manifestations of heart failure. Although the hypertrophic response normalizes cardiac wall stress, it seems that this response is not necessary to maintain contractile function. 3 Thus, targeting hypertrophic signaling pathways could possibly prevent or delay pathological remodeling and heart failure progression, irrespective of the inciting stimulus.
Glycogen synthase kinase (GSK)-3␤ is thought to be a key integrator of many of the pathways activated by hypertrophic stimuli. 4, 5 Although GSK-3 has 2 isoforms, GSK-3␣ and GSK-3␤, the majority of studies have focused on GSK-3␤. The near exclusive focus on GSK-3␤ as the predominant isoform may have originated in two landmark studies in Drosophila that established GSK-3␤ as the dominant isoform for body patterning. 6, 7 Both isoforms are ubiquitously expressed and share 97% homology within their catalytic domains but differ at their N and C-terminal regions. 8 The two isoforms of GSK-3 have both distinct and redundant functions in the cell, 9 -13 but in cardiac development, GSK-3␤ is dominant. 14 GSK-3␣ knockout mice develop normally, consistent with full compensation by GSK-3␤ for loss of GSK-3␣ in cardiac development. In contrast, germ-line de-letion of GSK-3␤ is embryonic lethal, because of hyperproliferation of cardiomyoblasts that largely obliterate the right ventricular and left ventricular (LV) cavities. 14 The bias toward GSK-3␤ as the dominant isoform also applies to studies in the adult heart which have focused on GSK-3␤ as the key negative regulator of cardiac hypertrophy. GSK-3␤ is active in unstimulated cells. When GSK-3␤ phosphorylates its substrates, it typically leads to their inactivation. Multiple substrates have been identified, and several of these are proteins that appear to play central roles in cardiomyocyte hypertrophy and/or proliferation, including, eukaryotic protein synthesis initiation factor 2B (eIF2B), 15 ␤-catenin, 16, 17 c-myc, 18 nuclear factor of activated T-cells (NF-AT), 19 mammalian target of rapamycin complex 1 (mTORC1), 20, 21 and cyclin D1. 22 Phosphorylation of these and other substrates by active GSK-3␤ is believed to blunt hypertrophy. On activation of hypertrophic signaling pathways such as PI3K/Akt, PKC, and PKA, GSK-3 is phosphorylated and inactivated 1, 4 and this inactivation releases the substrates from inhibition.
In reality, however, it is unclear whether the two isoforms share redundant or distinct functions with regard to hypertrophy and remodeling in the adult heart. Studies to date in the heart have led to confusing and sometimes contradictory conclusions concerning the role of the GSK-3 family in hypertrophy. 5 This appears to be due, in large part, to the methods used in these studies, including the use of small molecule ATP-competitive inhibitors such as the indirubins with questionable selectivity (leading to off-target effects) and/or limited solubility, 23, 24 or reliance on transgenic overexpression of constitutively active (CA) or dominant negative mouse models. [25] [26] [27] [28] [29] [30] [31] Therefore, the true roles of GSK-3␤ in the heart of adult mice in vivo remain to be defined.
To address this, we use a cardiomyocyte-specific, conditional knockout (KO) model to better define the role of GSK-3␤ in pathological hypertrophy and remodeling in the adult. Based on the majority of the published data discussed above, we expected that there would be exaggerated hypertrophy in response to thoracic aortic constriction (TAC) and, possibly, in response to myocardial infarction (MI). Herein, we demonstrate that GSK-3␤, per se, plays at most a minor role in regulating pathological cardiac hypertrophy induced by pressure overload. In contrast, GSK-3␤ is central to the hypertrophic response following MI. More importantly, despite the exaggerated hypertrophic response to MI in the remote myocardium, we find that deletion of GSK-3␤ protects against the LV dilatation and dysfunction that follows a large MI. Finally, we find that cardiomyocyte-specific deletion of GSK-3␤ identifies a key role for the kinase in regulating cardiomyocyte proliferation in the setting of stress.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
C57Bl6 mice with lox-p sites flanking exon 2 of the gsk-3␤ gene 12 were crossed with mice carrying the Mer-Cre-Mer transgene driven by the ␣-myosin heavy chain promoter (gift from Dr J. Molkentin, Cincinnati Children's Hospital, Cincinnati, Ohio). For TAC studies, at 5 weeks of age, the mice were treated with tamoxifen (20 mg/kg IP [Sigma-Aldrich] dissolved at a final concentration of 4 mg/mL in 30% ethanol in sterile PBS) or vehicle (30% ethanol in PBS) for 5 days to induce excision of exon 2. At 7 weeks of age, mice underwent baseline echo followed by TAC. In contrast to a prior report, 32 baseline LV function with this protocol was not compromised in the conditional KO (Online Table I and data not shown). For MI studies, we wanted to avoid impacting on infarct size so we administered tamoxifen for 5 days, beginning 3 days after occlusion of the proximal left anterior descending coronary artery.
Results

Deletion of GSK-3␤ in the Conditional Knockout Mouse
To clarify the role of GSK-3␤ in pressure overload-induced hypertrophy and post-MI remodeling, we first examined the degree of deletion of GSK-3␤ in our model. The GSK-3␤ fl/fl / Cre mice treated with vehicle (flox/Cre/V) demonstrated levels of GSK-3␤ protein expression that were comparable to the GSK-3␤ fl/fl mice lacking mer-cre-mer treated with tamoxifen (referred to as flox/Ϫ/T). This confirms that there was no significant "leaky" excision of exon 2 in the absence of tamoxifen in our model.
The GSK-3␤ fl/fl /Creϩ tamoxifen treated mice (referred to as flox/Cre/T or KO) had a range of reduction of GSK-3␤ protein expression in their left ventricles (LV) ( Figure 1 ). Residual GSK-3␤ protein ranged from 8% to The regression lines relating LVSP to HW/BW were not significantly different between the groups, suggesting deletion of GSK-3␤ did not affect the hypertrophic response. For flox/Cre/T (KO) mice, rϭ0.373; for flox/Ϫ/T mice, rϭ0.386. nϭ26 mice in each group. B, Hypertrophy in mice with mild, moderate, or severe TAC. Mice were subjected to TAC and HW/BW was determined at euthanasia. There is no difference in hypertrophy between KO and controls at any LVSP. Mean LVSPs for the groups are shown below the figure. C, Representative hematoxylin/eosinstained LV sections from mice with systolic pressures between 150 to 180 mm Hg, 3 weeks after TAC. Quantification of myocyte cross-sectional area is shown in the graph below. Cardiomyocyte size was not significantly different between the two control groups (flox/Ϫ/T mice and flox/Cre/V mice); therefore, these data were grouped together. nϭ200 cardiomyocytes/mouse with 8 mice as controls and 6 conditional KO mice. All morphometric measurements (HW, BW, LVM, HW/BW, LVM/BW) from TAC groups were significantly different from sham groups (PϽ0.05).
40% of control GSK-3␤ expression in our model and the average residual protein was 23% (nϭ114 mice). The residual GSK-3␤ protein expression is attributable to incomplete recombination and the presence of nonmyocytes in the hearts. Mice that had less than 30% residual GSK-3␤ protein expression by western blot were included in the study.
Effect of Deletion of GSK-3␤ on Pressure-Overload Hypertrophy
The mice then underwent TAC. Three weeks after TAC, mice were analyzed for cardiac function and morphometrics. Mice were catheterized with a high fidelity pressure transducer to determine the LV systolic pressure (LVSP) (Online Table I ). LVSP was comparable among the three groups, suggesting that the degree of TAC was also comparable in the groups. Heart weight (HW), left ventricle mass (LVM), and body weight (BW) were determined, and calculated HW/BW and left ventricle mass/BW (the primary morphometric measures of hypertrophy) were calculated. There were no significant differences in any of these parameters among the three groups that underwent TAC (Table) . We then analyzed HW/BW ratio in relation to LVSP (Figure 2A ). The regression lines relating LVSP to HW/BW were virtually identical, consistent with deletion of GSK-3␤ having little or no effect on the hypertrophic response. Next, we compared hypertrophy in mice with lower versus higher LVSPs to see whether deletion of GSK-3␤ might modulate hypertrophy differently in these groups ( Figure 2B ). There was no significant difference in hypertrophy in the KO mice in any of the ranges of LVSP.
To examine hypertrophy at the cellular level, we measured cross-sectional area of hematoxylin/eosin-stained LV sections and found no significant increase in cardiomyocyte size in the conditional KO ( Figure 2C ). We also measured the surface area of isolated cardiomyocytes and found no difference between the conditional KO and the control groups (Online Figure I) . Finally, we examined the fetal gene program and found that expression of atrial natriuretic peptide and ␤-myosin heavy chain were approximately 5-fold higher in the control compared to the KO (Online Figure II , A). These findings, which are contrary to numerous studies using transgenesis, suggest GSK-3␤ is not a central regulator of the hypertrophic response to pressure overload, whether the pressure load is mild, moderate or severe.
GSK-3␤ Deletion Does Not Affect Cardiac Function or Extracellular Matrix Remodeling After Pressure Overload Stress
We also assessed cardiac function by echocardiography both before and 3 weeks after TAC (Online Table II ). As noted, there was no significant difference in the ejection fraction (EF) between the groups before TAC. Furthermore, there was no difference in EF between groups of mice exposed to more severe pressure overload (LVSP 150 to 190 mm Hg) (Online Figure III , A) or in mice with less severe pressure overload (LVSPϭ120 to 150 mm Hg) (Online Figure III, B) . Analysis of contractility also failed to detect any differences between the groups in ϩdP/dt (a more sensitive measure of contractility) and ϪdP/dt (a sensitive measure of relaxation) (Online Table I ).
Studies have suggested that GSK-3␤ is antifibrotic. 30 ,33 However, we found no difference in the percent area of fibrosis between the treatment groups in LVSP-matched hearts (150 to 180 mm Hg) at 3 weeks after TAC (Online Figure IV) . Therefore, deletion of GSK-3␤ in cardiomyocytes does not appear to affect fibrosis, at least in the early phases of the response to pressure overload in the heart. 
GSK-3␤ Deletion Affects Several Signaling Pathways
Taken together, the data presented above suggest two possibilities: 1) the small amount of residual expression of GSK-3␤ in the conditional KO is sufficient to maintain normal functions of GSK-3␤, or 2) GSK-3␤ plays at most a minor role in the response to pressure overload. Therefore we examined signaling pathways regulated by GSK-3␤ reasoning that if possibility 1 were the case, signaling pathways would not be significantly dysregulated in the KO. We first analyzed phosphorylation of glycogen synthase at serine 641 and found a striking reduction in the KO (Figure 3 ). This finding identifies GSK-3␤ as the dominant isoform regulating glycogen synthesis in the heart, but more importantly demonstrates that the magnitude of reduction in GSK-3␤ expres-sion levels is sufficient to lead to dysregulation of signaling pathways.
To explore this further, we examined activity status of GSK-3␣ and downstream targets of GSK-3␤ known to play a role in the hypertrophic response. We found that GSK-3␣ protein levels and activity level (the latter as determined by phosphorylation at serine 21) were not different between GSK-3␤ KO and WT hearts, confirming no compensation (data not shown). Further, we examined the status of several GSK-3␤ targets that are known regulators of hypertrophy. We found a statistically significant decrease in phosphorylation of eiF2B (a direct target of GSK-3␤), and an increase in c-myc expression (which is normally downregulated by GSK-3␤-triggered proteasomal degradation) in LV lysates obtained 24 hours post- Figure V, A and B) . Thus, the decreased levels of GSK-3␤ were impacting on target activity, but this was not sufficient to lead to enhanced hypertrophy. One reason for this may be that deletion of GSK-3␤ did not lead to activation of mTORC1, a central regulator of the hypertrophic response (data not shown). In summary, we conclude that GSK-3␤ is not a central regulator of pressure overload (PO)-induced hypertrophy.
TAC (Online
GSK-3␤ Regulates Post-MI Remodeling
We next asked whether GSK-3␤ might regulate the other major form of remodeling in the heart: post-MI remodeling. We subjected KO mice and controls to permanent ligation of the proximal LAD. Because GSK-3␤ has been implicated in regulating acute ischemic injury (reviewed elsewhere 34, 35 ), and we specifically wanted to examine post-MI remodeling, tamoxifen (or vehicle) injections were begun 3 days after MI, at a time when the infarct was completed. We followed the mice for 8 weeks with periodic echocardiography. The infarcts produced were quite extensive in size ( Figure 4A ). Of note, the absolute length of the scar was not different between the KO and various controls, suggesting infarct size was comparable among the groups (KO: 1226Ϯ64 pixels, nϭ7 mice; Control: 1257Ϯ88 pixels, nϭ12 mice; pϭNS). Also supporting this conclusion, ejection fraction was virtually identical among the groups at one week post-MI ( Figure 4B ). In fact, at one week post-MI, LV end diastolic diameter (LVEDD) was greater in the KO, suggesting infarct size might have been slightly larger in the KO. However, beginning at 2 weeks post-MI, LVEF tended to be greater, and LVEDD tended to be smaller in the KO (Figure 4B ). At 4 weeks post-MI and after, LVEF was better maintained in the KO, and at Ն6 weeks, LV dilatation (LVEDD) was significantly less. Thus deletion of GSK-3␤ protects against post-MI remodeling.
We wanted to examine contractile function more closely, so we performed invasive hemodynamic testing at 8 weeks post-MI. For these studies we present the various controls as one group because there were no significant differences between them in any parameter. We found no significant differences between KO and controls in LVSP or LVEDP, but ϩdP/dt and -dP/dt were significantly increased in the KO ( Figure 5A through 5D ). Thus LV function, both systolic and diastolic, are better maintained in the KO.
We next wanted to understand potential mechanisms of this protective effect of deletion of GSK-3␤. Because smaller infarcts did not seem to account for the differences, we focused on the noninfarcted remote myocardium. Surprisingly, we found that overall HW/BW was significantly increased in the KO, suggesting that in the setting of post-MI remodeling, as opposed to TAC, GSK-3␤ is indeed antihypertrophic ( Figure 6A ). This increased hypertrophy was due, in large part, to cardiomyocyte hypertrophy because crosssectional area of the KO myocytes was significantly increased ( Figure 6B) . Despite the increased hypertrophy in the KO, fibrosis was not increased (data not shown) and apoptosis was significantly reduced ( Figure 6C) . As for the fetal gene program, ␤-myosin heavy chain was increased in the KO, consistent with the increased hypertrophy, but atrial natriuretic peptide and brain natriuretic peptide, which are also markers of hemodynamic stress, were not increased in the KO (Online Figure II, B) . The above data, taken together, suggest that the hypertrophy seen in the remote myocardium of the KO is more consistent with physiological, as opposed to pathological, hypertrophy. LVSP (A), LVEDP (B) , ϩdP/dt (C), and -dP/dt (D) were determined in the KO and various controls by catheterization at 8 weeks post-MI as described in Methods. Sham (MIϪ) is also shown. Again, there were no differences between the various controls so they were grouped together.
GSK-3␤ Deletion Increases Cardiomyocyte Proliferation
Deletion of GSK-3␤ blocks differentiation and promotes proliferation in mouse embryonic stem cells in culture. 9, 14, 36 Although a small molecule inhibitor of GSK-3 has been reported to lead to increased proliferation of neonatal rat ventricular myocytes (NRVMs) and adult rat ventricular myocytes (ARVMs) in culture, 37 the only in vivo study to date, which used expression of a CA mutant, reported that GSK-3␤ did not regulate cardiomyocyte proliferation in the adult heart. 30 To examine this further, we analyzed cardiomyocyte proliferation in LV heart sections both after TAC and post-MI by injecting mice with bromodeoxyuridine (BrdUrd) and then immuno-staining sections for BrdUrd. In the KO mice subjected to TAC, we found a significant increase in cells that were positive for BrdUrd ( Figure 7A ). All of the BrdUrd-positive nuclei overlapped with DRAQ5, a nuclear stain. Confocal analysis confirmed that the majority of the proliferating cells were from a cardiomyocyte lineage, based on positive staining for troponin (Tn)I ( Figure 7B ). The increased cardiomyocyte proliferation in the KO was confirmed with staining for the M-phase marker, phosphorylated histone H3. Rates of positivity with this technique were 0.63Ϯ0.11% for KO (nϭ7 mice); 0.07Ϯ0.03% for flox/Ϫ/T (nϭ5 mice); and 0.05Ϯ0.03 for flox/Cre/V (nϭ3 mice) PϽ0.001 for KO versus both controls. We also examined cardiomyocyte proliferation in the KO hearts post-MI (at 4 weeks) and found a similar increase in BrdUrdpositive/TnI-positive cells compared to controls ( Figure 7C ). Thus, GSK-3␤ inhibits cardiomyocyte proliferation in the stressed adult heart.
Discussion
Our results indicate that GSK-3␤ does not play a central role in regulating the hypertrophic response to pressure overload but does inhibit hypertrophy following MI. Following deletion of GSK-3␤, despite the fact that hypertrophy is increased in the remote myocardium, apoptosis is reduced and cardiomyocyte proliferation is enhanced. At the organ level, LV dilatation is reduced and LV function is better-preserved.
Previous studies point to GSK-3␤ as a critical regulator of cardiac hypertrophy. 4, 15, 19, [25] [26] [27] [28] [29] [30] [31] (and reviewed elsewhere 1, 5 ), but all of the in vivo models used to reach this conclusion involved overexpression of WT, CA, or dominant negative mutants or knock-in of CA mutants. Transgenic models can lead to nonphysiologic protein-protein interactions, aberrant subcellular localization, and phosphorylation of protein substrates that are not physiological substrates. In addition, overexpressed GSK-3␤ can subsume the physiological roles of GSK-3␣, making it impossible to decipher isoformspecific functions. Finally, the CA GSK-3␤ mutant (with a Ser 9 to Ala mutation) can still be inhibited by the canonical Wnt pathway and by a novel p38-MAPK mediated mechanism, clouding interpretation of findings. 38 -40 To attempt to clarify distinct GSK-3␤ isoform functions in pathological hypertrophy, we used a cardiac-specific, inducible GSK-3␤ knockout. Our model allows temporal control of GSK-3␤ deletion so we can specifically focus on the role of GSK-3␤ in the adult. We restricted our studies to mice with greater than 70% knockdown of GSK-3␤ protein expression in the heart. Average residual GSK-3␤ expression in these mice was Ϸ20%. Considering that nonmyocytes account for roughly 10% of heart mass, and GSK-3␤ is not deleted in (CSA) (B) were determined. n values for each group are shown below the graph. HW/BW and CSA were significantly greater in the KO compared to all other conditions. For determination of CSA, a minimum of 100 cardiomyocytes per heart were measured. *PϽ0.01 vs all other conditions; #PϽ0.01 vs all other conditions. C, Apoptosis in the remote myocardium. Heart sections from the remote myocardium of KO and control mice were stained with TnI and TUNEL and then counterstained with DAPI (nuclear stain). Rates of apoptosis are expressed as a percentage of total cardiomyocytes (TnI-positive cells). n for each group is shown below the graph. A minimum of 700 myocytes per heart were examined. these cells, residual GSK-3␤ expression in cardiomyocytes is more likely Ϸ10% to 15% of WT.
In the conditional KO, we did not see the expected exaggerated PO-induced hypertrophic phenotype. This is likely not attributable to inadequate deletion of GSK-3␤ because this level of deletion of GSK-3␤ did lead to increased hypertrophy in the post-MI model. This dichotomy between hypertrophic responses following TAC versus MI clearly suggests a complex pattern of isoform specificity versus redundancy for GSK-3␣ and GSK-3␤ in regulating these processes. 10 In the case of PO-induced hypertrophy, GSK-3␤ is not a central regulator.
In distinct contrast, GSK-3␤ appears to be the dominant isoform regulating post-MI hypertrophy and remodeling. Although infarct sizes were virtually identical in WT versus KO, hypertrophy was increased in the remote myocardium of the KO. The underlying mechanisms by which GSK-3␤ mediates post-MI hypertrophy but not PO hypertrophy are not clear but the data point to a very different milieu of cytokines, signaling factors, etc. recruited by the different hypertrophic stimuli. Of note, given the reduction in LV dilatation, better-preserved EF, no increase in fibrosis, and no increase in atrial natriuretic peptide or brain natriuretic peptide in the KO, this hypertrophy may be viewed as more "physiological" than "pathological."
The third key finding of this study is that GSK-3␤ regulates cardiomyocyte proliferation. One prior study concluded that GSK-3␤ regulates cardiomyocyte proliferation; however, this study was done in vitro and used a commercially available small molecule inhibitor 37 (BIO). This agent has a poorly-defined selectivity profile and also inhibits both isoforms of GSK-3, making it impossible to decipher isoform-specific effects.
Herein, we found that deletion of GSK-3␤ in cardiomyocytes in vivo in the setting of pressure overload led to a 3-to 4-fold increase in BrdUrd-positive cardiomyocytes compared to control mice subjected to TAC. In the post-MI KO hearts, absolute rates of BrdUrd positivity were higher compared to TAC, but the relative fold increase in KO compared to controls was similar. It is impossible at this time to determine what, if any, role this enhanced proliferation had on the phenotypes of the KOs, but it is clear that GSK-3␤ deletion increases cardiomyocyte proliferation in the setting of pressure overload and MI just as it does in embryonic stem cells and in cardiomyocytes in the developing heart. 14 We did not examine proliferation in progenitor cell populations committed to the cardiomyocyte lineage, but it seems likely that cell cycling in these populations would be increased as well and would contribute to the BrdUrdϩ/TnIϩ population we measured.
Our findings may have potential implications for treatment of patients post-MI and for regenerative therapies. Traditional therapeutics to prevent post-MI remodeling following a large MI (eg, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists) are effective to some degree but progression to congestive heart failure or death, despite standard approaches, is common. Deletion of GSK-3␤ beginning Ϸ1 week after MI partially prevented the decline in EF, ϩdP/dt, and -dP/dt. Thus, although the difference in LVEF in our study at 8 weeks post-MI was modest (6 to 7 EF points), it is important to note that in the large angiotensinconverting enzyme inhibitor trials such as SOLVD, SAVE, and GISSI-3, even a 5 point difference in EF was associated with a significant reduction in mortality. [41] [42] [43] Mortality at 8 weeks post-MI in our series was reduced by 25% in the knockout, although this did not achieve statistical significance by Kaplan-Meier analysis. Maybe more importantly, LV dilatation is a major predictor of progression to CHF and death. Whereas the LVEDD in the WT mice increased by 78%, the increase in the KO was only 48%, consistent with much less remodeling. Again, in the large clinical trials, increases of Ϸ10% in LV volume were associated with significantly worse outcomes. [41] [42] [43] Although direct comparisons between our studies and clinical trials are obviously impossible, it is important to understand how critical even modest differences in LVEF and LV volume can be. Given the near-total lack of important drug development in heart failure in the past 10ϩ years, novel strategies need to be identified. It is conceivable that GSK-3␤ inhibition could be one such strategy.
Finally, the findings related to GSK-3 isoform specificity versus redundancy in function could translate to superior strategies for regenerative therapies. Cardiomyocyte proliferation occurs at a very low level throughout life, 44 but increases in the heart in response to stress (reviewed elsewhere [45] [46] ). Cardiac progenitor cells and/or small immature cardiomyocytes proliferate following pressure overload and myocardial infarction. The present beliefs held in the field are that although these cells proliferate and progenitor cells do differentiate into cardiomyocytes, this occurs at too slow of a rate to keep up with the rate of cell death so that the net decrease of cells plays a role in the progression of heart failure. Strategies to manipulate progenitor cell behavior in situ by modulating activity of various kinases are being explored. 47, 48 GSK-3␤ inhibition could increase cardiomyocyte proliferation and perhaps keep pace with cell death rates, thereby preventing progression to heart failure. In addition, based on our earlier findings which show that inhibition of GSK-␤ promotes embryonic stem cell proliferation whereas active GSK-␤ promotes differentiation into the cardiomyocyte lineage, 9, 10, 14, 49 periodic withdrawal of a GSK-␤ inhibitor could help drive progenitor differentiation into cardiomyocytes. That said, targeting both GSK-3␣ and GSK-␤ long-term with small molecule inhibitors raises concerns over promoting cancer by enhancing ␤-catenin signaling. Selective targeting of individual isoforms (ie, GSK-3␤) could, however, maintain normal ␤-catenin signaling 9 while allowing increased cardiomyocyte proliferation.
Sources of Funding
This work was supported by National Heart, Lung, and Blood Institute grant HL061688 and by donations from The Kahn Foundation and the Scarperi family (to T.F.), Canadian Institutes of Health Research grants MOP12858 and 74711 (to J.R.W.), and American Heart Association Grant 0715281U (to K.C.W.).
